Alkermes (NASDAQ:ALKS) Price Target Raised to $43.00

Alkermes (NASDAQ:ALKS) had its price objective hoisted by Wells Fargo & Company from $37.00 to $43.00 in a report released on Thursday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

ALKS has been the topic of a number of other research reports. Zacks Research lowered Alkermes from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 19th. Deutsche Bank Aktiengesellschaft lowered their target price on Alkermes from $55.00 to $45.00 and set a “buy” rating on the stock in a research note on Thursday, November 13th. Truist Financial upped their price target on Alkermes from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday, November 17th. Wolfe Research began coverage on Alkermes in a report on Monday, February 23rd. They set an “outperform” rating and a $45.00 price target for the company. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Alkermes in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $44.07.

Alkermes Price Performance

Shares of Alkermes stock opened at $30.10 on Thursday. The firm’s fifty day simple moving average is $31.54 and its 200-day simple moving average is $30.22. Alkermes has a 12 month low of $25.17 and a 12 month high of $36.32. The stock has a market capitalization of $5.02 billion, a price-to-earnings ratio of 21.05 and a beta of 0.49.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.29 earnings per share for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.14). Alkermes had a return on equity of 14.91% and a net margin of 16.37%.The business had revenue of $384.55 million for the quarter, compared to analyst estimates of $380.44 million. During the same quarter in the prior year, the company earned $1.05 EPS. The firm’s revenue for the quarter was down 10.6% on a year-over-year basis. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. Analysts anticipate that Alkermes will post 1.31 earnings per share for the current year.

Insiders Place Their Bets

In other Alkermes news, Director Shane Cooke sold 61,200 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $34.57, for a total value of $2,115,684.00. Following the completion of the transaction, the director owned 103,744 shares in the company, valued at approximately $3,586,430.08. This represents a 37.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Craig C. Hopkinson sold 9,000 shares of the firm’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $33.93, for a total value of $305,370.00. Following the completion of the sale, the executive vice president directly owned 57,740 shares of the company’s stock, valued at approximately $1,959,118.20. This trade represents a 13.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 148,148 shares of company stock worth $5,028,378 in the last ninety days. 4.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Alkermes

A number of institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada grew its position in Alkermes by 117.2% during the first quarter. Royal Bank of Canada now owns 275,526 shares of the company’s stock worth $9,098,000 after buying an additional 148,696 shares during the period. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Alkermes during the 1st quarter worth approximately $213,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Alkermes by 4.3% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 482,332 shares of the company’s stock worth $15,927,000 after acquiring an additional 20,091 shares in the last quarter. State of New Jersey Common Pension Fund D grew its holdings in shares of Alkermes by 15.1% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 62,677 shares of the company’s stock worth $1,793,000 after acquiring an additional 8,214 shares during the period. Finally, Envestnet Asset Management Inc. increased its stake in Alkermes by 1.3% in the 2nd quarter. Envestnet Asset Management Inc. now owns 43,658 shares of the company’s stock valued at $1,249,000 after purchasing an additional 551 shares in the last quarter. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Trending Headlines about Alkermes

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Analyst optimism — Wells Fargo raised its price target to $43 and kept an overweight stance, signaling bullish analyst conviction that shares have meaningful upside. Wells Fargo raises price target to $43
• Positive Sentiment: RBC still rates ALKS “outperform” and keeps a high price target ($45 after a small cut), indicating continued buy-side support from some sell-side analysts. RBC maintains outperform, lowers PT to $45
• Neutral Sentiment: CEO succession announced — Alkermes disclosed a leadership transition plan; such changes create short-term uncertainty but may be neutral-to-positive over time depending on execution. Alkermes announces CEO succession plan
• Neutral Sentiment: Revenue roughly in line/beat estimates while EPS missed — top-line results were not the primary problem; profitability and EPS dynamics drove the negative reaction. See earnings highlights and call transcript for detail. Q4 2025 earnings highlights
• Negative Sentiment: Earnings miss and downbeat near-term outlook — reported EPS (~$0.29) missed the ~$0.43 consensus and management set FY2026 EPS guidance in negative territory, undercutting the bull case and spurring the sell-off. Shares down after earnings miss
• Negative Sentiment: Market reaction — shares declined sharply on the news and trading volume picked up, reflecting short-term repositioning by investors. Coverage pieces and call transcripts detail investor pushback. ALKS down despite mixed results, leadership change
• Neutral Sentiment: Short-interest reporting in feeds shows inconclusive/zeroed data for February (no actionable signal from that dataset). Short interest note

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.